Argenx SE

Belgian-Dutch biopharmaceutical company specialising in immunology

ARGX Euronext Brussels · home listing ARGX Nasdaq ISIN NL0010832176 SEC CIK 1697862 LEI 7245009C5FZE6G9ODQ71
Follow Argenx Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 USD · IFRS
EPS, diluted -

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · ESEF annual reports, IFRS
Revenue and net income6 fiscal years
  • Revenue
  • Net income
−$2B$0$2B$4B$6BFY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$4.2B$1.3B
FY24$2.2B$833M
FY23$1.2B−$295.1M
FY22$400.7M−$709.6M
FY21$497.3M−$408.3M
FY20$41.2M−$608.5M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−1500%−1000%−500%0%500%FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2589.1%25.4%31.1%
FY2489.6%−1%38.1%
FY2390.1%−35.7%−24.8%
FY2292.7%−179.8%−177.1%
FY21-−70.1%−82.1%
FY20-−1158.1%−1475.3%
Free cash flowOperating cash flow minus capital expenditure
−$1B−$500M$0$500M$1BFY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25$679M
FY24−$84.5M
FY23−$421.1M
FY22−$863.6M
FY21−$610.4M
FY20−$399.5M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Argenx
  • Healthcare median
−1500%−1000%−500%0%500%FY20FY21FY22FY23FY24FY25
Show the numbers
YearArgenxHealthcare median
FY2531.1%−30.6%
FY2438.1%−47%
FY23−24.8%−58%
FY22−177.1%−80.4%
FY21−82.1%−71.9%
FY20−1475.3%−62.2%